Gt Biopharma Inc Stock Price, News & Analysis

GT Biopharma reported its financial results for Q4 and the full year of 2021, highlighting a cash position of $32.0 million as of December 31, 2021, which provides funding into 2023 for clinical development of its lead products GTB-3650 and GTB-5550. The company presented novel TriKE® data at recent medical conferences, showing promising activation of NK cells against tumors. However, GT Biopharma reported a net loss of $18.0 million in Q4 and $58.0 million for the full year, significantly higher than the previous year's losses, raising concerns for investors.

GT Biopharma announced preclinical data for its TriKE product candidate, GTB-5550, indicating enhanced NK cell-mediated killing of myeloma cells. This was presented at the 48th European Society for Blood and Marrow Transplantation Annual Meeting. The study demonstrated that GTB-5550 significantly improves NK cell efficacy against multiple myeloma across various cell lines, including H929 and RPMI-8226. Combination therapies showed promising results, particularly with lenalidomide, while bortezomib did not enhance efficacy as expected. The findings support further clinical investigation of GTB-5550.

GT Biopharma, Inc. (NASDAQ: GTBP) presented promising preclinical data at ESMO's Targeted Anticancer Therapies Congress on its novel TriKE technology. The research demonstrates TriKE's ability to drive NK cell immunotherapy against non-small cell lung cancer (NSCLC) even in hypoxic environments. Notable findings include significant NK cell activity against NSCLC cells, regardless of disease stage. The company aims to further investigate the efficacy of mesothelin-targeted TriKE in combination with existing treatments, highlighting its potential in enhancing patient outcomes.

GT Biopharma, Inc. (NASDAQ: GTBP) announced participation in the 34th Annual ROTH Conference on March 15, 2022, at 8:30 AM PT. Dr. Greg Berk, President of R&D, Chief Medical Officer, and Interim CEO, will engage in a fireside chat and is available for one-on-one meetings. The conference features numerous 1-on-1 meetings, thematic panels, and presentations from about 400 companies. To schedule a meeting, contact oneononerequests@roth.com. For registration details, visit ROTH Conference Registration.

GT Biopharma (NASDAQ: GTBP) announced its participation in three key medical conferences showcasing its innovative TriKE® technology. The upcoming presentations include:

• ESMO Targeted Anticancer Therapies Congress: March 7-8, 2022, focusing on NK cell immunotherapy.
• 48th Annual EBMT: March 19-23, 2022, discussing TriKE against multiple myeloma.
• AACR Annual Meeting: April 8-13, 2022, highlighting TriKE’s role in treating head and neck cancers.

These conferences may bolster investor interest and enhance the company's visibility in the oncology sector.

GT Biopharma (NASDAQ: GTBP) announced the immediate appointment of Manu Ohri as its new Chief Financial Officer (CFO). With over 25 years of management and finance experience, Ohri's previous roles include CFO for various public companies and management consultant in the biotech sector. His expertise is expected to strengthen the company's financial management and enhance communication with capital markets. GT Biopharma recently reported positive data from first-in-human trials of its TriKE® platform, marking a significant milestone in its clinical development efforts.

GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company, announced that Dr. Greg Berk, President of R&D and Interim CEO, will participate in a Fireside Chat at the B. Riley Securities' Virtual Oncology Conference. The event is scheduled for January 27, 2022, at 9:30 A.M. EST. This conference will showcase innovations in immuno-oncology, particularly focusing on GT Biopharma's proprietary TriKE® NK cell engager platform, which aims to enhance the cancer-fighting abilities of natural killer cells. Further details and webcast information are available.

GT Biopharma, Inc. (NASDAQ: GTBP) has announced the approval of equity compensation awards to key employees as inducements to join the company, as per Nasdaq Listing Rule 5635(c)(4). The awards include options for Gavin Choy (227,500 shares at $3.05 each), Leslie Bransfield (75,000 shares at $3.05), and a stock award for Kathy Quandt (50,000 shares). The options have a 10-year term, with specific vesting schedules. GT Biopharma focuses on developing immuno-oncology therapies utilizing its TriKE® platform, licensed from the University of Minnesota.

GT Biopharma, Inc. (NASDAQ: GTBP) announced the availability of its mini-poster presentation at the ESMO Immuno-Oncology Congress 2021 in Geneva, Switzerland, from December 8-11, 2021. The presentation focuses on GTB-5550, a dual camelid nanobody that targets the B7-H3 molecule, showing effective NK cell activation against various tumors, including enzalutamide-resistant prostate cancer. The company is advancing its TriKE® technology platform, and GMP production of GTB-5550 has begun, indicating significant progress in its clinical pipeline.